Maverick Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

Maverick Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-35,869	Closed	-$206K	–	671
2021 Q2	$206K	Buy	+35,869	New	+$185K	﹤0.01%	481

Other funds holding CPRX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Maverick Capital's CPRX Position: Q3 2021 in Review

Maverick Capital sold out of Catalyst Pharmaceutical (CPRX) in Q3 2021, closing a stake of 35,869 shares — an estimated $206K sold.

Maverick Capital first reported a position in CPRX in Q2 2021 and held it in 1 quarter. The position peaked at $206K in Q2 2021. 144 funds tracked by Wall St. Rank hold CPRX as of Q3 2021.

Maverick Capital reported no remaining Catalyst Pharmaceutical position as of Q3 2021 after selling out during the quarter.
Maverick Capital sold 35,869 Catalyst Pharmaceutical shares in Q3 2021, an estimated $206K.
Maverick Capital first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 1 quarter.
Maverick Capital's Catalyst Pharmaceutical position peaked at $206K in Q2 2021.
144 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.